btlines

URT GPW Periodic report · PAP Biznes

Urteste SA (URT) · Q1 2026 results

Share price: 41.60 zł · 2026-11-10

Results Q1 2026 vs Q1 2025 · year over year · published 29 May 2026 and 29 May 2025

Net loss widened year on year. The report's language is unchanged.

Only a basic analysis is available for this company at the moment.

1 · Numbers

Loss widened

Net income vs Q1 2025

Net income -1.9M vs -740.0K

Revenue +63.1%

2 · How the report reads

Unchanged

Language tone vs last period

Report language: upbeat for a company report — about as upbeat as in Q1 2025.

Weak signal: formal report language, not a call.

3 · What stood out Nothing unusual flagged this period.

Official channels

The company's own website and social media accounts.

Read between the lines

No major shifts flagged this period.

Tone

How upbeat the language was, compared with other companiesiTone counts positive minus negative finance words, adjusted for length. Executives mostly speak positively, so the labels compare each call with every company's latest call: “typical” is the middle third, “very upbeat” the top tenth, “cautious” the bottom tenth.. Dot: Q1 2026. Ring: Q1 2025.

Report language Upbeat (was upbeat)

Upbeat for a company report — about as upbeat as in Q1 2025. Periodic reports carry legally required risk wording, so their tone moves little and is a weak signal.

Sentences that drove the tone
“NASTRO - an enzyme-based, low-cost IVD test for diagnosing early-stage breast cancer and international industrial property rights protection of a new breast diagnostic marker as well as...”
“The credit risk arising from changes in the interest rates of leasing costs has a negligible impact on the financial position of the Entity.”
“The risks are typical for the Company's current stage of development and will not be worse than expected in the near future.”

Full figures

PLN · PAP Biznes report (2026-05-29)

Metric Q1 2026 Q1 2025 Change
Revenue -52.0K -141.0K Loss narrowed
Operating income -1.8M -714.0K Loss widened
Net income -1.9M -740.0K Loss widened
EPS -1.22 -0.52 Loss widened
P/E 12-mo loss 12-mo loss —

Topics

Topics are drawn from the full report text, not management commentary.

Most discussed now

  • The most significant impact on the Company's operations in the coming years will be the costs of research and development activities.
  • The Company does not anticipate the completion of works related to the creation of the PANURI project before the end of the third quarter.
  • Assets measured at initial fair value through other comprehensive income – these are financial assets held under the model
  • The members of the Company's Management Board are not required to refrain from competing activities following the termination of the…

Faded since Q1 2025

  • Fading From among the diagnostic test prototypes held within the MULTI-CANCER project, the Company selected the NASTRO project (breast cancer…
  • Fading The total net value of the Project amounts to 20,820 thousand.
  • Fading Assets measured at initial fair value through other comprehensive income – these are financial assets held within a business model
  • Fading The objective of the project is to develop a medical device for in vitro use.

Latest announcements

Official filings, newest first.

Similar companies

Healthcare · Biotechnology
All Healthcare companies →